881844-09-3

Basic information

• Product Name: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine
• Synonyms: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine;4-PyridinaMine, 2-chloro-N-[(4-Methoxyphenyl)Methyl]-3-nitro-;2-chloro-N-(4-Methoxybenzyl)-3-nitropyridin-4-aMine;N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine-3
• CAS NO: 881844-09-3
• Molecular Formula: C₁₃H₁₂ClN₃O₃
• Molecular Weight: 293.70568
• Mol File: 881844-09-3.mol
• Article Data: 7

Chemical Properties

• Melting Point: 106 °C
• Boiling Point: 469.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.394±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 0.18±0.10(Predicted)
• CAS DataBase Reference: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine(881844-09-3)
• EPA Substance Registry System: N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine(881844-09-3)

Safety Data

• Hazardous Substances Data: 881844-09-3(Hazardous Substances Data)

Usage

General Description

N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine is a chemical compound with a complex molecular structure. It consists of a benzyl group attached to a nitropyridin-4-amine core, with a chlorine atom and a methoxy group also incorporated into the molecule. N-(4-methoxybenzyl)-2-chloro-3-nitropyridin-4-amine may have potential applications in pharmaceutical or chemical research, given its unique structure and functional groups. It is important to handle and utilize this chemical compound with care, following all necessary safety protocols and regulations to ensure proper handling and avoid potential hazards.

Upstream product

• 89282-12-2 2,4-dihydroxy-3-nitropyridine 
• 5975-12-2 2,4-dichloro-3-nitro-pyridine 
• 2393-23-9 4-methoxy-benzylamine 

Downstream Products

• 1012059-54-9 2-(6-bromobenzo[d][1,3]dioxol-5-ylthio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine 
• 1012059-49-2 4-Chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine-2-thiol 
• 1012059-50-5 4-amino-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine-2-thiol 
• 1061317-31-4 2-(7-iodo-2,3-dihydrobenzo[b][1,4]dioxin-6-ylthio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine 
• 1012059-57-2 2-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridin-4-amine 
• 1012059-50-5 4-amino-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine-2(3H)-thione 
• 1012059-49-2 4-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-c]pyridine-2(3H)-thione 
• 881844-10-6 2-chloro-N⁴-(4-methoxybenzyl)pyridine-3,4-diamine 
• 6811-77-4 3-deazaadenine 
• 881844-18-4 4-amino-3-[2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-7-nitro-3H-imidazo[4,5-c]pyridine 
• 881844-13-9 4-amino-1-[2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-7-nitro-1H-imidazo[4,5-c]pyridine 
• 881844-11-7 4-chloro-1-(p-methoxybenzyl)-1H-imidazo[4,5-c]pyridine 
• 881844-12-8 4-(isobutyrylamino)-1H-imidazo[4,5-c]pyridine 
• 3243-26-3 4-hydrazino-1H-imidazo[4,5-c]pyridine 

Relevant articles and documents

Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and in Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model

A series of 2,4-disubstituted imidazopyridines, originating from a SoftFocus Kinase library, was identified from a high throughput phenotypic screen against the human malaria parasite Plasmodium falciparum. Hit compounds showed moderate asexual blood stage activity. During lead optimization, several issues were flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, and cardiotoxicity and were addressed through structure-Activity and structure-property relationship studies. Pharmacokinetic properties were assessed in mice for compounds showing desirable in vitro activity, a selectivity window over cytotoxicity, and microsomal metabolic stability. Frontrunner compound 37 showed good exposure in mice combined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy in the P. falciparum NOD-scid IL-2Rnull (NSG) mouse model. Preliminary mechanistic studies suggest inhibition of hemozoin formation as a contributing mode of action.

Therapeutic compounds and uses thereof

The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders such as cancer.

HSP90 Inhibitors Containing a Zinc Binding Moiety

The present invention relates to HSP90 inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.